These findings may be explained by the strong association of inflammatory factors and extensive morphological changes with the occurrence and/or recurrence of SRD, thus patients with SRD have better improvement of macular structure by anti-VEGF treatment [13]. The gene discussed is VEGFA; the disease is dopa-responsive dystonia due to sepiapterin reductase deficiency.